troglitazone has been researched along with Cardiac Failure in 3 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These hemodynamic changes suggest that a single oral dose of troglitazone induced inotropy without activation of the sympathetic nervous system." | 6.70 | Troglitazone improves cardiac function in patients with congestive heart failure. ( Endo, A; Furuse, Y; Hisatome, I; Igawa, O; Ikawa, S; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C; Shimoyama, M; Uchida, K, 2002) |
| "These hemodynamic changes suggest that a single oral dose of troglitazone induced inotropy without activation of the sympathetic nervous system." | 2.70 | Troglitazone improves cardiac function in patients with congestive heart failure. ( Endo, A; Furuse, Y; Hisatome, I; Igawa, O; Ikawa, S; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C; Shimoyama, M; Uchida, K, 2002) |
| "The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity, although it was judged as safe during the clinical trial." | 2.41 | [Evaluation of thiazolidinedione derivative drugs for safety]. ( Iwata, M; Kobayashi, M, 2001) |
| "To determine, in patients with type 2 diabetes mellitus, whether an association exists between thiazolidinedione therapy or other diabetes therapies and hospital admission for heart failure." | 1.33 | Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. ( Bultemeier, NC; Hartung, DM; Haxby, DG; Touchette, DR, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ogino, K | 1 |
| Furuse, Y | 1 |
| Uchida, K | 1 |
| Shimoyama, M | 1 |
| Kinugawa, T | 1 |
| Osaki, S | 1 |
| Kato, M | 1 |
| Endo, A | 1 |
| Igawa, O | 1 |
| Hisatome, I | 1 |
| Ikawa, S | 1 |
| Shigemasa, C | 1 |
| Hartung, DM | 1 |
| Touchette, DR | 1 |
| Bultemeier, NC | 1 |
| Haxby, DG | 1 |
| Kobayashi, M | 1 |
| Iwata, M | 1 |
1 review available for troglitazone and Cardiac Failure
| Article | Year |
|---|---|
[Evaluation of thiazolidinedione derivative drugs for safety].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Edema; Heart Fa | 2001 |
1 trial available for troglitazone and Cardiac Failure
| Article | Year |
|---|---|
Troglitazone improves cardiac function in patients with congestive heart failure.
Topics: Blood Pressure; Cardiac Output; Catecholamines; Chromans; Cross-Over Studies; Diabetes Mellitus, Typ | 2002 |
1 other study available for troglitazone and Cardiac Failure
| Article | Year |
|---|---|
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
Topics: Adult; Aged; Case-Control Studies; Chromans; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospi | 2005 |